PARP Inhibitors in Reproductive System Cancers: Current Use and Developments

@inproceedings{Coyne2016PARPII,
  title={PARP Inhibitors in Reproductive System Cancers: Current Use and Developments},
  author={Geraldine O’Sullivan Coyne and Alice Chen and Robert S. Meehan and James H. Doroshow},
  booktitle={Drugs},
  year={2016}
}
The repair of DNA damage is a critical cellular process governed by multiple biochemical pathways that are often found to be defective in cancer cells. The poly(ADP-ribose) polymerase (PARP) family of proteins controls response to single-strand DNA breaks by detecting these damaged sites and recruiting the proper factors for repair. Blocking this pathway forces cells to utilize complementary mechanisms to repair DNA damage. While PARP inhibition may not, in itself, be sufficient to cause tumor… CONTINUE READING
24
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

  • International journal of biological sciences
  • 2019
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Niraparib: First Global Approval

VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 100 REFERENCES

and Drug Administration (FDA)

US Foo
  • FDA grants accelerated approval to new treatment for advanced ovarian cancer [media release]. 19 Dec
  • 2016
VIEW 18 EXCERPTS
HIGHLY INFLUENTIAL

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  • The New England journal of medicine
  • 2016
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL